Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib in Korean Patients
Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib in Korean Patients
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases. Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Ankylosing Spondylitis (AS) is a form of chronic arthritis causing inflammation in the spine. This can cause pain and stiffness in the back. Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the body's immune system mistakenly attacking healthy joint tissue causing inflammation, joint damage, disability, and a reduced life expectancy. This study will assess the adverse events and change in disease symptoms in Korean participants with RA, AD, AS or PsA.
Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis or psoriatic arthritis. Korean participants who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 3600 participants will be enrolled this study, in multiple sites within Korea.
Participants will receive Upadacitinib as prescribed by the physician and will be followed for approximately 28 weeks.
There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.
Inclusion Criteria:
Exclusion Criteria:
- Participants for whom the drug is contraindicated in the approved local label.
Cheonan-si, Chungcheongnam-do 31116, South Korea
Cheonan-si, Chungcheongnam-do 31151, South Korea
Cheonan-si, Chungcheongnam-do 31151, South Korea
Daejeon, Daejeon Gwang Yeogsi 35233, South Korea
Daejeon, Daejeon Gwang Yeogsi 35233, South Korea
Wŏnju, Gang Weondo 26426, South Korea
Wŏnju, Gang Weondo 26426, South Korea
Bucheon-si, Gyeonggido 14647, South Korea
Bucheon-si, Gyeonggido 14647, South Korea
Incheon, Gyeonggido 22711, South Korea
Suwon, Gyeonggido 16247, South Korea
Suwon, Gyeonggido 16247, South Korea
Uijeongbu-si, Gyeonggido 11759, South Korea
Uijeongbu-si, Gyeonggido 11759, South Korea
Uijeongbu-si, Gyeonggido 11765, South Korea
Daegu, Gyeongsangbuk-do 42472, South Korea
Daegu, Gyeongsangbuk-do 42601, South Korea
Daegu, Gyeongsangbuk-do 42601, South Korea
Changwon-si, Gyeongsangnam-do 51394, South Korea
Changwon-si, Gyeongsangnam-do 51472, South Korea
Incheon, Incheon Gwang Yeogsi 21431, South Korea
Incheon, Incheon Gwang Yeogsi 21431, South Korea
Incheon, Incheon Gwang Yeogsi 21431, South Korea
Jeollabuk-do, Jeonrabugdo 54910, South Korea
Chungbuk, North Chungcheong 28641, South Korea
Sejong-si, Sejong-si 30099, South Korea
Sejong-si, Sejong-si 30099, South Korea
Dongjak-gu, Seoul Teugbyeolsi 06973, South Korea
Dongjak-gu, Seoul Teugbyeolsi 06973, South Korea
Seoul, Seoul Teugbyeolsi 03722, South Korea
Seoul, Seoul Teugbyeolsi 06591, South Korea
Seoul, Seoul Teugbyeolsi 06591, South Korea
Seoul, Seoul Teugbyeolsi 07345, South Korea
Seoul, Seoul Teugbyeolsi 07441, South Korea
Seoul, Seoul Teugbyeolsi 07441, South Korea